TARGETED THERAPY WITH BRENTUXIMAB VEDOTIN IN RELAPSED AND REFRACTORY FORMS OF CLASSICAL HODGKIN LYMPHOMA

Modern first-line therapy programs can cure about 80% of patients with classical Hodgkin lymphoma at any stage of the disease, but 10-30% of patients is refractory and need to continue treatment. The treatment standard for relapsed or refractory forms of classical Hodgkin lymphoma is the second-line chemotherapy with high-dose consolidation under the protection of autologous blood stem cells, but the efficacy of such therapy does not exceed 50% for the entire group of refractory patients. The release of target drugs specific for Berezovsky-Reed-Sternberg tumor cells opens up new prospects for the treatment of classical Hodgkin lymphoma. The article reviews the studies of the use of a new target drug Brentuximab Vedotin for the treatment of relapsed and refractory forms of classical Hodgkin lymphoma.